Michael Colwill, Richard Pollok, Chandni Radia, Leighton J Seal, Andrew Poullis
{"title":"Clinical and Psychosocial Burden of Inflammatory Bowel Disease Among Transgender Individuals: A National BioResource Cohort Study.","authors":"Michael Colwill, Richard Pollok, Chandni Radia, Leighton J Seal, Andrew Poullis","doi":"10.2147/CEG.S633494","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Transgender and gender non-conforming (TGNC) individuals are under-represented in inflammatory bowel disease (IBD) research, and little is known about their diagnostic experiences, disease burden, mental health comorbidity, or quality of life (QoL). We therefore aimed to characterise clinical features, diagnostic timelines, comorbidity, and QoL among TGNC people with IBD and to contextualise key outcomes using a matched cisgender cohort.</p><p><strong>Patients and methods: </strong>We conducted a nationwide cohort study within the IBD BioResource population. Using questionnaires and linked BioResource data, we collected information on demographics, clinical history, gender-affirming care, comorbidity, and QoL. TGNC participants were matched to cisgender controls by sex and age category for a contextual and exploratory comparison. Analyses were performed using regression models.</p><p><strong>Results: </strong>Thirty-nine TGNC participants responded (46.2% Crohn's disease, 43.6% ulcerative colitis, 10.3% IBD-unclassified). Median time from symptom onset to diagnosis was 10.5 months (interquartile range 6.0-18.0), 62.3% reported prior hospitalisation and 28.2% prior IBD surgery. Psychiatric comorbidity was frequent (79%). Gender-affirming hormone therapy was reported in 30.7% and prior gender-affirming surgery in 17.9%. Matched analyses demonstrated a trend towards longer diagnostic delays and higher rates of hospitalisation and IBD-related surgery in TGNC participants. Psychiatric comorbidity was significantly higher (79.5% vs 56.8%, <i>p</i>=0.033). QoL impairment was substantial and broadly comparable between groups.</p><p><strong>Conclusion: </strong>TGNC individuals with IBD demonstrated a high burden of psychiatric comorbidity and signals of longer diagnostic timelines and poorer disease control compared with cisgender peers. These findings highlight potential disparities across IBD care pathways and underscore the need for larger, dedicated studies.</p>","PeriodicalId":10208,"journal":{"name":"Clinical and Experimental Gastroenterology","volume":"19 ","pages":"633494"},"PeriodicalIF":2.6000,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13641002/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/CEG.S633494","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Transgender and gender non-conforming (TGNC) individuals are under-represented in inflammatory bowel disease (IBD) research, and little is known about their diagnostic experiences, disease burden, mental health comorbidity, or quality of life (QoL). We therefore aimed to characterise clinical features, diagnostic timelines, comorbidity, and QoL among TGNC people with IBD and to contextualise key outcomes using a matched cisgender cohort.
Patients and methods: We conducted a nationwide cohort study within the IBD BioResource population. Using questionnaires and linked BioResource data, we collected information on demographics, clinical history, gender-affirming care, comorbidity, and QoL. TGNC participants were matched to cisgender controls by sex and age category for a contextual and exploratory comparison. Analyses were performed using regression models.
Results: Thirty-nine TGNC participants responded (46.2% Crohn's disease, 43.6% ulcerative colitis, 10.3% IBD-unclassified). Median time from symptom onset to diagnosis was 10.5 months (interquartile range 6.0-18.0), 62.3% reported prior hospitalisation and 28.2% prior IBD surgery. Psychiatric comorbidity was frequent (79%). Gender-affirming hormone therapy was reported in 30.7% and prior gender-affirming surgery in 17.9%. Matched analyses demonstrated a trend towards longer diagnostic delays and higher rates of hospitalisation and IBD-related surgery in TGNC participants. Psychiatric comorbidity was significantly higher (79.5% vs 56.8%, p=0.033). QoL impairment was substantial and broadly comparable between groups.
Conclusion: TGNC individuals with IBD demonstrated a high burden of psychiatric comorbidity and signals of longer diagnostic timelines and poorer disease control compared with cisgender peers. These findings highlight potential disparities across IBD care pathways and underscore the need for larger, dedicated studies.
目的:跨性别和性别不符合(TGNC)个体在炎症性肠病(IBD)研究中的代表性不足,对他们的诊断经历、疾病负担、心理健康合并症或生活质量(QoL)知之甚少。因此,我们的目的是表征TGNC合并IBD患者的临床特征、诊断时间表、合并症和生活质量,并使用匹配的顺性别队列来确定关键结果。患者和方法:我们在IBD生物资源人群中进行了一项全国性队列研究。通过问卷调查和相关的生物资源数据,我们收集了人口统计学、临床病史、性别确认护理、合并症和生活质量的信息。TGNC参与者按性别和年龄类别与顺性别对照组相匹配,以进行背景和探索性比较。采用回归模型进行分析。结果:39名TGNC参与者有反应(46.2%为克罗恩病,43.6%为溃疡性结肠炎,10.3%为ibd未分类)。从症状出现到诊断的中位时间为10.5个月(四分位数范围为6.0-18.0),62.3%报告有住院史,28.2%报告有IBD手术史。精神合并症很常见(79%)。30.7%的人接受过性别确认激素治疗,17.9%的人接受过性别确认手术。匹配分析表明,TGNC参与者的诊断延迟时间更长,住院率和ibd相关手术率更高。精神合并症明显高于对照组(79.5% vs 56.8%, p=0.033)。两组间的生活质量损害是实质性的,具有广泛的可比性。结论:与顺性别同侪相比,TGNC IBD患者表现出较高的精神合并症负担、较长的诊断时间和较差的疾病控制。这些发现强调了IBD治疗途径之间的潜在差异,并强调了进行更大规模、专门研究的必要性。